These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12930146)

  • 1. Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
    Le Diguarher T; Chollet AM; Bertrand M; Hennig P; Raimbaud E; Sabatini M; Guilbaud N; Pierré A; Tucker GC; Casara P
    J Med Chem; 2003 Aug; 46(18):3840-52. PubMed ID: 12930146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
    Zhang YM; Fan X; Xiang B; Chakravarty D; Scannevin R; Burke S; Karnachi P; Rhodes K; Jackson P
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3096-100. PubMed ID: 16632358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
    Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
    Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
    Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
    Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
    J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.
    Tamura Y; Watanabe F; Nakatani T; Yasui K; Fuji M; Komurasaki T; Tsuzuki H; Maekawa R; Yoshioka T; Kawada K; Sugita K; Ohtani M
    J Med Chem; 1998 Feb; 41(4):640-9. PubMed ID: 9484512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.
    Breuer E; Salomon CJ; Katz Y; Chen W; Lu S; Röschenthaler GV; Hadar R; Reich R
    J Med Chem; 2004 May; 47(11):2826-32. PubMed ID: 15139760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.
    Zhang YM; Fan X; Chakaravarty D; Xiang B; Scannevin RH; Huang Z; Ma J; Burke SL; Karnachi P; Rhodes KJ; Jackson PF
    Bioorg Med Chem Lett; 2008 Jan; 18(1):409-13. PubMed ID: 17981034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo.
    Kapischke M; Fischer T; Tiessen K; Tschesche H; Bruch HP; Kalthoff H; Kruse ML
    Int J Oncol; 2008 Jan; 32(1):273-82. PubMed ID: 18097568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach.
    Takahashi K; Ikura M; Habashita H; Nishizaki M; Sugiura T; Yamamoto S; Nakatani S; Ogawa K; Ohno H; Nakai H; Toda M
    Bioorg Med Chem; 2005 Jul; 13(14):4527-43. PubMed ID: 15908222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: exploration of P2 quinazoline substituents.
    Nilsson M; Belfrage AK; Lindström S; Wähling H; Lindquist C; Ayesa S; Kahnberg P; Pelcman M; Benkestock K; Agback T; Vrang L; Terelius Y; Wikström K; Hamelink E; Rydergård C; Edlund M; Eneroth A; Raboisson P; Lin TI; de Kock H; Wigerinck P; Simmen K; Samuelsson B; Rosenquist S
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4004-11. PubMed ID: 20541405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
    Cheng XC; Wang Q; Fang H; Tang W; Xu WF
    Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From model complexes to metalloprotein inhibition: a synergistic approach to structure-based drug discovery.
    Puerta DT; Schames JR; Henchman RH; McCammon JA; Cohen SM
    Angew Chem Int Ed Engl; 2003 Aug; 42(32):3772-4. PubMed ID: 12923840
    [No Abstract]   [Full Text] [Related]  

  • 15. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors.
    Brockunier LL; He J; Colwell LF; Habulihaz B; He H; Leiting B; Lyons KA; Marsilio F; Patel RA; Teffera Y; Wu JK; Thornberry NA; Weber AE; Parmee ER
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4763-6. PubMed ID: 15324904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors.
    Borzilleri RM; Cai ZW; Ellis C; Fargnoli J; Fura A; Gerhardt T; Goyal B; Hunt JT; Mortillo S; Qian L; Tokarski J; Vyas V; Wautlet B; Zheng X; Bhide RS
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1429-33. PubMed ID: 15713401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.
    Gould AE; Adams R; Adhikari S; Aertgeerts K; Afroze R; Blackburn C; Calderwood EF; Chau R; Chouitar J; Duffey MO; England DB; Farrer C; Forsyth N; Garcia K; Gaulin J; Greenspan PD; Guo R; Harrison SJ; Huang SC; Iartchouk N; Janowick D; Kim MS; Kulkarni B; Langston SP; Liu JX; Ma LT; Menon S; Mizutani H; Paske E; Renou CC; Rezaei M; Rowland RS; Sintchak MD; Smith MD; Stroud SG; Tregay M; Tian Y; Veiby OP; Vos TJ; Vyskocil S; Williams J; Xu T; Yang JJ; Yano J; Zeng H; Zhang DM; Zhang Q; Galvin KM
    J Med Chem; 2011 Mar; 54(6):1836-46. PubMed ID: 21341678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.
    Mesaros EF; Thieu TV; Wells GJ; Zificsak CA; Wagner JC; Breslin HJ; Tripathy R; Diebold JL; McHugh RJ; Wohler AT; Quail MR; Wan W; Lu L; Huang Z; Albom MS; Angeles TS; Wells-Knecht KJ; Aimone LD; Cheng M; Ator MA; Ott GR; Dorsey BD
    J Med Chem; 2012 Jan; 55(1):115-25. PubMed ID: 22141319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs.
    Cuniasse P; Devel L; Makaritis A; Beau F; Georgiadis D; Matziari M; Yiotakis A; Dive V
    Biochimie; 2005; 87(3-4):393-402. PubMed ID: 15781327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of novel potent hepatitis C virus NS3 protease inhibitors: discovery of 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a N-acyl-L-hydroxyproline bioisostere.
    Thorstensson F; Wångsell F; Kvarnström I; Vrang L; Hamelink E; Jansson K; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Jan; 15(2):827-38. PubMed ID: 17107807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.